SurroMed, Inc. Expands Global Efforts with New Singapore Facility
Surromed Pte Ltd. Dedicates Advanced Research and Development
Facility in Singapore
Surromed Pte Ltd. Dedicates Advanced Research and Development
Facility in Singapore
Mountain View, California and Singapore, September 24, 2001/ PRNewswire/ SurroMed, Inc. today announced that its wholly-owned subsidiary SurroMed Pte Ltd. is dedicating its advanced research and development facility in Singapore. The Singapore facility will undertake cutting edge research and development relating to SurroMed's Nanobarcodes[TM] particle technology and the application of this technology to miniaturized and multiplexed analysis of biological molecules. SurroMed's Nanobarcodes technology is an integrated component of SurroMed's unique platform for comprehensive phenotypic analysis and biological marker discovery.
"We have attracted a multidisciplinary team of world class technical talent in Singapore," said Dennis Polla, Ph.D., President of SurroMed Pte Ltd. "With the help of the Singapore Economic Development Board and the National Science and Technology Board we have very quickly built and equipped our state of the art facility. We currently employ 20 professionals in Singapore, and we will be considering opportunities to expand our efforts here in Singapore."
"SurroMed Pte Ltd. focuses on development of a critical component of our technologies that enable more precise diagnosis and treatment of human disease and complements research that we will conduct at SurroMed, Inc. in our facility in Mountain View, California. We will benefit from the technical capability of the Singapore scientific community and the life sciences infrastructure in place in Singapore," said Gordon Ringold, Ph.D, CEO and Chairman of SurroMed, Inc. "SurroMed and its principals have a longstanding relationship with the Economic Development Board and the National Science and Technology Board. We look forward to being an important part of the effort to make Singapore a life sciences center of excellence, and we are excited about the strategic opportunities our investment in Singapore afford us."
About Nanobarcodes[TM] Particle Technology
SurroMed's Nanobarcodes particle technology uses cylindrically-shaped colloidal metal nanoparticles, in which the metal composition can be alternated along the length, and in which the size of each metal segment can be controlled. Intrinsic differences in reflectivity between the metal segments allow individual particles to be identified by conventional optical microscopy. Nanobarcodes particles can be functionalized with various capture chemistries to bind specifically to target molecules that can be interrogated in solution and on surfaces using conventional techniques. This approach enables the creation of an extremely diverse range of uniquely identifiable Nanobarcodes particles that can be used for miniaturized and multiplexed analysis of biological molecules, such as proteins, peptides and organic molecules. For more information, please visit https://www.surromed.com/Technology.html.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Talya Gould
Account Executive
(415) 677-4455 ext.284
email: [email protected]
"We have attracted a multidisciplinary team of world class technical talent in Singapore," said Dennis Polla, Ph.D., President of SurroMed Pte Ltd. "With the help of the Singapore Economic Development Board and the National Science and Technology Board we have very quickly built and equipped our state of the art facility. We currently employ 20 professionals in Singapore, and we will be considering opportunities to expand our efforts here in Singapore."
"SurroMed Pte Ltd. focuses on development of a critical component of our technologies that enable more precise diagnosis and treatment of human disease and complements research that we will conduct at SurroMed, Inc. in our facility in Mountain View, California. We will benefit from the technical capability of the Singapore scientific community and the life sciences infrastructure in place in Singapore," said Gordon Ringold, Ph.D, CEO and Chairman of SurroMed, Inc. "SurroMed and its principals have a longstanding relationship with the Economic Development Board and the National Science and Technology Board. We look forward to being an important part of the effort to make Singapore a life sciences center of excellence, and we are excited about the strategic opportunities our investment in Singapore afford us."
About Nanobarcodes[TM] Particle Technology
SurroMed's Nanobarcodes particle technology uses cylindrically-shaped colloidal metal nanoparticles, in which the metal composition can be alternated along the length, and in which the size of each metal segment can be controlled. Intrinsic differences in reflectivity between the metal segments allow individual particles to be identified by conventional optical microscopy. Nanobarcodes particles can be functionalized with various capture chemistries to bind specifically to target molecules that can be interrogated in solution and on surfaces using conventional techniques. This approach enables the creation of an extremely diverse range of uniquely identifiable Nanobarcodes particles that can be used for miniaturized and multiplexed analysis of biological molecules, such as proteins, peptides and organic molecules. For more information, please visit https://www.surromed.com/Technology.html.
About SurroMed, Inc.
Headquartered in Mountain View, California, SurroMed uses its integrated phenotyping and biological marker discovery platform to better understand the root causes of disease and the factors underlying patient-to-patient variations in disease presentation, progression and response to therapy. Discoveries arising from its research will enable improved, cost-efficient discovery and development of therapeutic and diagnostic products. SurroMed's phenotyping and biological marker discovery platform incorporates advanced proprietary technologies for profiling and analysis of hundreds of immune cell populations, proteins and low-molecular-weight organic molecules (such as sugars, peptides or lipids) in small volumes of blood and/or other biological samples, while maintaining complete patient confidentiality. By capturing and analyzing enormous amounts of clinical and biological information in a massively parallel fashion to identify useful biological markers, SurroMed plans to enable the precise diagnosis and effective treatment of disease.
Contacts:
SurroMed, Inc.
August J. Moretti
CFO and General Counsel
(650) 230-1564
email: [email protected]
Noonan/Russo Communications, Inc.
Talya Gould
Account Executive
(415) 677-4455 ext.284
email: [email protected]